Publication: 2931

Publication: 2931

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Breast Cancer Res Treat vol 171 (2) 325-34

Year:: 2018
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 8

Parents:: 2469
Children:: None

Program:: CCP
Primary Committee:: Older Adult
Sec. Committees:: Breast Health Outcomes

Pharmas:
Grants:: UG1CA189823, 30CA033572, U10CA180790, U10CA180795, U10CA180820, CA180795, U10CA180836, U10CA180838, U10CA180857, U10CA180858, U10CA180867, U10CA180888, CA180858

Corr. Author:
Authors:: Daneng Li Linda M. McCall Olwen M Hahn Clifford A. Hudis Harvey J. Cohen Hyman B. Muss Aminah Jatoi Jacqueline M. Lafky Karla V. Ballman Eric P. Winer Debu Tripathy Bryan Schneider William Barry Maura N. Dickler Arti Hurria

Networks:: CA043, LAPS-CT018, LAPS-IL057, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-TX035, NY018

Study: CALGB-40503
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: